Study to Assess the Clinical Efficacy and Safety of Intravitreal Aflibercept Injection (IAI;EYLEA®;BAY86-5321) in Patients With Branch Retinal Vein Occlusion (BRVO)
Last updated on July 2021Recruitment
- Recruitment Status
- Completed
- Estimated Enrollment
- 180
Summary
- Conditions
- Branch Retinal Vein Occlusion
- Type
- Interventional
- Phase
- Phase 3
- Design
- Allocation: RandomizedIntervention Model: Parallel AssignmentMasking: Double (Participant, Outcomes Assessor)Primary Purpose: Treatment
Participation Requirements
- Age
- Between 18 years and 125 years
- Gender
- Both males and females
Description
Not Provided
Not Provided
Tracking Information
- NCT #
- NCT01521559
- Collaborators
- Bayer
- Investigators
- Study Director: Clinical Trial Management Regeneron Pharmaceuticals
Get Well Soon